Aquestive Therapeutics (AQST) SEC Filings: History & Chart

Aquestive Therapeutics, Inc.(AQST)

Drug Manufacturers - Specialty & Generic · Warren, NJ

$4.57-0.00 (-0.11%)

Delayed quote: Oct 6, 2026, 1:50 PM EDT

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

Warren, NJ

147 employees

www.aquestive.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Daniel Barber

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 29, 2026	Sep 29, 2026	View filing
8-K	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 17, 2026	Sep 17, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 11, 2026	Sep 11, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 9, 2026	Sep 9, 2026	View filing
4	Sep 8, 2026	Sep 8, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 17, 2026	Aug 17, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 10, 2026	Aug 10, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
424B3	Jul 9, 2026	Jul 9, 2026	View filing
EFFECT	Jul 8, 2026	Jul 9, 2026	View filing
S-3	Jun 26, 2026	Jun 26, 2026	View filing
4	Jun 24, 2026	Jun 24, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
8-K	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	May 19, 2026	May 19, 2026	View filing
4	May 18, 2026	May 18, 2026	View filing

SEC Filings

Recent Filings